X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (433) 433
oncology (416) 416
humans (373) 373
male (248) 248
female (226) 226
melanoma (202) 202
middle aged (195) 195
aged (166) 166
adult (165) 165
surgery (133) 133
melanoma - drug therapy (114) 114
cancer (109) 109
melanoma - pathology (106) 106
animals (103) 103
isolated limb perfusion (89) 89
prognosis (87) 87
skin neoplasms - pathology (86) 86
melphalan (83) 83
aged, 80 and over (80) 80
skin neoplasms - drug therapy (77) 77
treatment outcome (76) 76
interferon-gamma (75) 75
melphalan - administration & dosage (71) 71
malignant-melanoma (70) 70
tumor necrosis factor-alpha - administration & dosage (70) 70
tnf-alpha (68) 68
cutaneous melanoma (66) 66
neoplasm staging (66) 66
melanoma - mortality (65) 65
rats (64) 64
survival (62) 62
chemotherapy, cancer, regional perfusion (57) 57
tumor-necrosis-factor (55) 55
melanoma - surgery (54) 54
medicine & public health (53) 53
skin neoplasms - mortality (53) 53
disease-free survival (52) 52
chemotherapy (51) 51
chemotherapy, cancer, regional perfusion - methods (49) 49
metastatic melanoma (49) 49
extremities (48) 48
immunotherapy (48) 48
sarcoma (48) 48
therapy (48) 48
hematology, oncology and palliative medicine (47) 47
antineoplastic agents - therapeutic use (46) 46
melanoma - secondary (46) 46
abridged index medicus (45) 45
combined modality therapy (45) 45
survival rate (44) 44
metastasis (43) 43
lymphatic metastasis (42) 42
adolescent (41) 41
follow-up studies (41) 41
time factors (41) 41
factor-alpha (40) 40
immunology (40) 40
survival analysis (40) 40
combination (38) 38
skin neoplasms - surgery (38) 38
trial (38) 38
adjuvant therapy (36) 36
medicine, research & experimental (36) 36
melanoma - therapy (36) 36
retrospective studies (36) 36
surgical oncology (36) 36
antineoplastic agents - administration & dosage (35) 35
pharmacology & pharmacy (35) 35
mice (34) 34
interferon-alpha - therapeutic use (32) 32
sarcoma - drug therapy (32) 32
analysis (31) 31
health aspects (31) 31
metastases (31) 31
tumor necrosis factor-alpha - therapeutic use (31) 31
antineoplastic agents, alkylating - administration & dosage (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
care and treatment (30) 30
interferon (30) 30
tumors (30) 30
lymph node excision (29) 29
chemotherapy, adjuvant (28) 28
prognostic-factors (28) 28
sentinel lymph node biopsy (28) 28
dose-response relationship, drug (27) 27
research (26) 26
high-risk melanoma (25) 25
lymph nodes - pathology (25) 25
melphalan - therapeutic use (25) 25
biopsy (24) 24
human-melanoma (24) 24
necrosis-factor-alpha (24) 24
tnf (24) 24
interleukin-2 (23) 23
ipilimumab (23) 23
neoplasm metastasis (23) 23
risk factors (23) 23
antineoplastic agents, alkylating - therapeutic use (22) 22
cell biology (22) 22
interferon-alpha (22) 22
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF TRANSLATIONAL MEDICINE, ISSN 1479-5876, 01/2019, Volume 17
Conference Proceeding
JOURNAL OF TRANSLATIONAL MEDICINE, ISSN 1479-5876, 01/2018, Volume 16
Conference Proceeding
Hematological Oncology, ISSN 0278-0232, 06/2017, Volume 35, Issue S2, pp. 28 - 29
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 08/2018, Volume 379, Issue 6, pp. 593 - 595
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 01/2017, Volume 376, Issue 4, pp. 399 - 399
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 09/2014, Volume 25
Conference Proceeding
NATURE REVIEWS CLINICAL ONCOLOGY, ISSN 1759-4774, 11/2014, Volume 11, Issue 11
Journal Article
MOLECULAR CANCER THERAPEUTICS, ISSN 1535-7163, 11/2013, Volume 12, Issue 11
Conference Proceeding
FEBS JOURNAL, ISSN 1742-464X, 07/2013, Volume 280, pp. 618 - 619
Conference Proceeding
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 101 - 105
The spectacular outcomes of the phase III trials regarding nivolumab versus ipilimumab in fully resected stage IIIB/C–IV and of the combination of dabrafenib... 
Nivolumab | Ipilimumab | Melanoma | Dabrafenib | Randomised trials | Adjuvant therapy | Trametinib | RANDOMIZED-TRIALS | COMPLETE RESECTION | PHASE-III TRIAL | INTERFERON-ALPHA | ANTI-PD-1 THERAPY | ONCOLOGY | TUMOR BURDEN | CUTANEOUS MELANOMA | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | ROTTERDAM CRITERIA | Antineoplastic Agents, Immunological - administration & dosage | Predictive Value of Tests | Skin Neoplasms - drug therapy | Humans | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Practice Patterns, Physicians | Patient Selection | Pyridones - administration & dosage | Time Factors | Skin Neoplasms - mortality | Clinical Decision-Making | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Ipilimumab - administration & dosage | Skin Neoplasms - pathology | Risk Factors | Treatment Outcome | Melanoma - pathology | Evidence-Based Medicine | Randomized Controlled Trials as Topic | Interferons - administration & dosage | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Pyrimidinones - administration & dosage | Neoplasm Staging | Melanoma - mortality | Care and treatment | Oncology, Experimental | Interferon | Research | Biological response modifiers | Cancer | Risk groups | Toxicity | Decision making | Clinical trials | Exploration | Cancer therapies | Patients | Survival | Clinical outcomes | Lymph nodes | Risk management | Lymph | Index Medicus
Journal Article
CANCER, ISSN 0008-543X, 03/2014, Volume 120, Issue 6, pp. 781 - 789
Effective management of hepatic metastases from ocular and cutaneous melanoma remains a major therapeutic challenge. Treatment options include hepatic... 
ISOLATED HEPATIC PERFUSION | cutaneous melanoma | perfusion | chemoembolization | ARTERIAL CHEMOEMBOLIZATION | IMPROVED SURVIVAL | SINGLE-CENTER | OPEN-LABEL | hepatic intra-arterial infusion | systemic therapy | PHASE-II TRIAL | UVEAL MELANOMA | MEK INHIBITION | ONCOLOGY | review | ocular melanoma | DACARBAZINE BOLD | hepatic metastases | surgery
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 19, pp. 1845 - 1855
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 06/2015, Volume 16, Issue 6, pp. E262 - E262
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 06/2016, Volume 17, Issue 6, pp. E223 - E223
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
A blinded trial involving patients with resected stage III melanoma showed that adjuvant pembrolizumab every 3 weeks for a year was associated with a 1-year... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ANTI-PD-1 THERAPY | EORTC 18952 | TUMOR BURDEN | CUTANEOUS MELANOMA | PHASE-3 TRIAL | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | IPILIMUMAB | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Survival Rate | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Melanoma - drug therapy | Intention to Treat Analysis | Quality of Life | Aged | B7-H1 Antigen - analysis | Infusions, Intravenous | Melanoma - surgery | Neoplasm Staging | Melanoma - mortality | Diagnosis | Drug therapy | Patients | Health aspects | Melanoma | Medical research | Lymphatic system | Risk groups | PD-1 protein | Committees | Metastasis | Survival | Skin cancer | Pembrolizumab | Hospitals | Motivation | PD-L1 protein | Myositis | Death | Mutation | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Placebos | Placebos (Medicine) | Adjuvant treatment of cancer | Tractament adjuvant del càncer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 522 - 530
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.